Package Leaflet: Information for the User
Tyverb 250 mg film-coated tablets
lapatinib
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Tyverb is used to treat some types of breast cancer(those that overexpress HER2 receptors) that have spread beyond the original tumor or to other organs (advanced or metastatic breast cancer). This medicine may slow down or stop the growth of cancer cells, or it may destroy them.
Tyverb is prescribed to be taken in combination with other anticancer medicines.
Tyverb is prescribed in combination with capecitabinein patients who have received prior treatment for advanced or metastatic breast cancer. Prior treatment for metastatic breast cancer must have included trastuzumab.
Tyverb is prescribed in combination with trastuzumabin patients with metastatic breast cancer who are hormone receptor negative and have received prior treatment for metastatic breast cancer.
Tyverb is prescribed in combination with an aromatase inhibitorin patients with hormone-sensitive metastatic breast cancer(breast cancer that is more likely to grow in the presence of hormones), for whom chemotherapy is not suitable.
Information about these medicines is described in separate package leaflets. Ask your doctorto provide you with information about these medicines.
Do not take Tyverb
Be cautious with Tyverb
Your doctor will perform tests to check that your heart is working properlybefore and during treatment with Tyverb.
Before taking Tyverb, tell your doctor if you have any heart problems.
Before starting Tyverb, your doctor also needs to know:
Your doctor will perform tests to check that your liver is working properlybefore and during treatment with Tyverb.
Tell your doctorif you are in any of these situations.
Severe skin reactions
Severe skin reactions have been observed with the use of Tyverb. Symptoms may include skin rash, blisters, and skin peeling.
Tell your doctor as soon as possible if you experience any of these symptoms.
Other medicines and Tyverb
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.This includes herbal medicines and medicines that you buy without a prescription.
It is especially important that you tell your doctorif you are using or have recently used any of the following medicines. Some medicines may affect how Tyverb works or Tyverb may affect how other medicines work. These medicines include medicines from the following groups:
Tell your doctorif you are using or have recently used any of these medicines.
Your doctor will review the medicines you are taking to ensure that you are not taking any medicine that should not be taken with Tyverb. Your doctor will advise you if there is an alternative available.
Taking Tyverb with food and drinks
Do not drink grapefruit juice while you are being treated with Tyverb. It may affect how this medicine works.
Pregnancy and breast-feeding
Tyverb should not be used during pregnancy unless your doctor specifically recommends it.
It is not known if Tyverb passes into breast milk. Do not breast-feed while you are taking Tyverb and for at least 5 days after the last dose.
If you have any doubts, ask your doctor or pharmacistbefore taking Tyverb.
Driving and using machines
You are responsible for deciding whether you are able to drive a vehicle or perform tasks that require high concentration. Due to the possible side effects of Tyverb, your ability to drive or operate machinery may be affected. These effects are described in section 4, "Possible side effects".
Tyverb contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Follow exactly the instructions for administration of this medicine given by your doctor.If you are unsure, consult your doctor or pharmacist again.
Your doctor will decide the correct dose of Tyverb depending on the type of breast cancer you are being treated for.
If you are prescribed Tyverb in combination with capecitabine,the usual dose is 5 Tyverb tablets per day,in a single dose.
If you are prescribed Tyverb in combination with trastuzumab,the usual dose is 4 Tyverb tablets per day,in a single dose.
If you are prescribed Tyverb in combination with an aromatase inhibitor, the usual dose is 6 Tyverb tablets per day, in a single dose.
Take the dose that has been prescribed for you every day for as long as your doctor tells you.
Your doctor will inform you about the dose of the other anticancer medicine and how to take it.
Taking the tablets
While you are taking Tyverb
If you take more Tyverb than you should
Contact your doctor or pharmacist immediately. If possible, show them the pack.
If you forget to take Tyverb
Do not take a double doseto make up for forgotten doses. Take the next dose at the scheduled time.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
A severe allergic reaction is arare side effect that may affect up to 1 in 1,000 people and may appear quickly.
Symptoms may include:
Tell your doctor immediatelyif you have any of these symptoms. Do not take any more tablets.
Very common side effects(may affect more than 1 in 10 people)
Tell your doctor immediatelyif you have any sign of diarrhea, as it is very important that diarrhea is treated immediately. Also, tell your doctor immediately if diarrhea gets worse.
Tell your doctor if you have a skin rash.
Other very common side effects:
Tell your doctorif any of these side effects get serious or troublesome.
Common side effects(may affect up to 1 in 10 people):
In most cases, the effect on your heart will not have any symptoms. If you experience symptoms associated with this side effect, they may include irregular heartbeat and difficult breathing.
Tell your doctor if you have any of these symptoms.
Uncommon side effects(may affect up to 1 in 100 people):
Tell your doctor immediatelyif you have any of these symptoms.
Other uncommon side effects include:
Rare side effects(may affect up to 1 in 1,000 people):
Frequency not known (cannot be estimated from the available data):
If you have other side effects
Tell your doctor or pharmacistif you notice any side effects not mentioned in this leaflet.
Reducing the risk of diarrhea and skin rash
Tyverb may cause severe diarrhea
If you have diarrhea while taking Tyverb:
Tell your doctorif your diarrhea continues.
Tyverb may cause skin rash
Your doctor will perform skin checks before and during treatment.
To care for sensitive skin:
Tell your doctorif you have a skin rash.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if it is possible that they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister or carton.
Do not store above 30°C.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Tyverb composition
Appearance of the product and container contents
Tyverb film-coated tablets are oval, biconvex, yellow, film-coated, with "GS XJG" engraved on one side.
Tyverb is supplied in blister packs or bottles:
Blister packs
Each Tyverb pack contains 70 or 84 tablets in an aluminum blister pack of 10 or 12 tablets. Each blister pack has a perforation in the middle that allows them to be divided into two blister packs of 5 or 6 tablets, depending on the pack size.
Tyverb is also available in multiple packs with 140 tablets, which contain 2 boxes of 70 tablets.
Bottles
Tyverb is also available in plastic bottles containing 70, 84, 105 or 140 tablets.
Only some pack sizes may be marketed.
Marketing authorization holder
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland
Manufacturer
Lek Pharmaceuticals d.d.
Verovškova 57
1526 Ljubljana
Slovenia
Novartis Pharmaceutical Manufacturing LLC
Verovškova ulica 57
1000 Ljubljana
Slovenia
Novartis Pharma GmbH
Roonstraße 25
D-90429 Nuremberg
Germany
Glaxo Wellcome, S.A.
Avda. Extremadura, 3
09400 Aranda de Duero, Burgos
Spain
Novartis Farmacéutica S.A.
Gran Via de les Corts Catalanes, 764
08013 Barcelona
Spain
You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder:
Belgium Novartis Pharma N.V. Tel: +32 2 246 16 11 | Lithuania SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16 50 |
Novartis Bulgaria EOOD Tel: +359 2 489 98 28 | Luxembourg Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11 |
Czech Republic Novartis s.r.o. Tel: +420 225 775 111 | Hungary Novartis Hungária Kft. Tel.: +36 1 457 65 00 |
Denmark Novartis Healthcare A/S Tlf: +45 39 16 84 00 | Malta Novartis Pharma Services Inc. Tel: +356 2122 2872 |
Germany Novartis Pharma GmbH Tel: +49 911 273 0 | Netherlands Novartis Pharma B.V. Tel: +31 88 04 52 555 |
Estonia SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 810 | Norway Novartis Norge AS Tlf: +47 23 05 20 00 |
Greece Novartis (Hellas) A.E.B.E. Τηλ: +30 210 281 17 12 | Austria Novartis Pharma GmbH Tel: +43 1 86 6570 |
Spain Novartis Farmacéutica, S.A. Tel: +34 93 306 42 00 | Poland Novartis Poland Sp. z o.o. Tel.: +48 22 375 4888 |
France Novartis Pharma S.A.S. Tél: +33 1 55 47 66 00 | Portugal Novartis Farma - Produtos Farmacêuticos, S.A. Tel: +351 21 000 8600 |
Croatia Novartis Hrvatska d.o.o. Tel. +385 1 6274 220 | Romania Novartis Pharma Services Romania SRL Tel: +40 21 31299 01 |
Ireland Novartis Ireland Limited Tel: +353 1 260 12 55 | Slovenia Novartis Pharma Services Inc. Tel: +386 1 300 75 50 |
Iceland Vistor hf. Sími: +354 535 7000 | Slovakia Novartis Slovakia s.r.o. Tel: +421 2 5542 5439 |
Italy Novartis Farma S.p.A. Tel: +39 02 96 54 1 | Finland Novartis Finland Oy Puh/Tel: +358 (0)10 6133 200 |
Cyprus Novartis Pharma Services Inc. Τηλ: +357 22 690 690 | Sweden Novartis Sverige AB Tel: +46 8 732 32 00 |
Latvia SIA Novartis Baltics Tel: +371 67 887 070 | United Kingdom (Northern Ireland) Novartis Ireland Limited Tel: +44 1276 698370 |
Date of last revision of this leaflet:
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.